Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quantitative high-throughput analysis of tumor infiltrating lymphocytes in breast cancer.
Hayashi K, Nogawa D, Kobayashi M, Asakawa A, Ohata Y, Kitagawa S, Kubota K, Takahashi H, Yamada M, Oda G, Nakagawa T, Uetake H, Onishi I, Kinowaki Y, Kurata M, Kitagawa M, Yamamoto K. Hayashi K, et al. Among authors: kinowaki y. Front Oncol. 2022 Sep 5;12:901591. doi: 10.3389/fonc.2022.901591. eCollection 2022. Front Oncol. 2022. PMID: 36132149 Free PMC article.
Overview of Ferroptosis and Synthetic Lethality Strategies.
Kinowaki Y, Taguchi T, Onishi I, Kirimura S, Kitagawa M, Yamamoto K. Kinowaki Y, et al. Int J Mol Sci. 2021 Aug 27;22(17):9271. doi: 10.3390/ijms22179271. Int J Mol Sci. 2021. PMID: 34502181 Free PMC article. Review.
Stratification of lung squamous cell carcinoma based on ferroptosis regulators: Potential for new therapeutic strategies involving ferroptosis induction.
Asakawa A, Kawade G, Kurata M, Fukuda S, Onishi I, Kinowaki Y, Ishibashi S, Ikeda M, Watabe S, Kobayashi M, Ishibashi H, Okubo K, Kitagawa M, Yamamoto K. Asakawa A, et al. Among authors: kinowaki y. Lung Cancer. 2022 Mar;165:82-90. doi: 10.1016/j.lungcan.2022.01.012. Epub 2022 Jan 24. Lung Cancer. 2022. PMID: 35101731
Spatial and Quantitative Analysis of Tumor-Associated Macrophages: Intratumoral CD163-/PD-L1+ TAMs as a Marker of Favorable Clinical Outcomes in Triple-Negative Breast Cancer.
Shinohara H, Kobayashi M, Hayashi K, Nogawa D, Asakawa A, Ohata Y, Kubota K, Takahashi H, Yamada M, Tokunaga M, Kinugasa Y, Oda G, Nakagawa T, Onishi I, Kinowaki Y, Kurata M, Ohashi K, Kitagawa M, Yamamoto K. Shinohara H, et al. Among authors: kinowaki y. Int J Mol Sci. 2022 Oct 31;23(21):13235. doi: 10.3390/ijms232113235. Int J Mol Sci. 2022. PMID: 36362023 Free PMC article.
31 results